<abstract xmlns="http://www.w3.org/1999/xhtml"><p>The novel coronavirus disease, 2019 (COVID – 19) evolved as an unprecedented pandemic. The severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) infection has been associated with significantly deranged coagulation parameters and increased incidence of thrombotic events. Deranged coagulation parameters, such as D-dimers and fibrin degradation products, can indicate a poor prognosis, and their measurement will help stratify the patients according to the disease severity, need of intensive care unit admission, and prediction of the clinical course. Gaps in understanding the natural history of the disease cause difficulties in tailoring therapies and optimizing the management of patients. Lack of specific treatment further complicates this situation. While thrombotic events can cause significant morbidity and mortality in patients, a focused approach to the prevention and treatment of venous thromboembolism (VTE) can, to a great extent, decrease the disease burden caused by thrombotic diseases. Pharmacological prophylactic anticoagulants and mechanical therapies such as pneumatic compression devices can help prevent venous thromboembolism and other thrombotic events. Thrombotic events due to COVID-19, their prevention and management, are the focus of this paper, with the prospect of providing insights into this relatively unexplored area.</p></abstract>

The novel coronavirus disease, 2019 (COVID – 19) evolved as an unprecedented pandemic. The severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) infection has been associated with significantly deranged coagulation parameters and increased incidence of thrombotic events. Deranged coagulation parameters, such as D-dimers and fibrin degradation products, can indicate a poor prognosis, and their measurement will help stratify the patients according to the disease severity, need of intensive care unit admission, and prediction of the clinical course. Gaps in understanding the natural history of the disease cause difficulties in tailoring therapies and optimizing the management of patients. Lack of specific treatment further complicates this situation. While thrombotic events can cause significant morbidity and mortality in patients, a focused approach to the prevention and treatment of venous thromboembolism (VTE) can, to a great extent, decrease the disease burden caused by thrombotic diseases. Pharmacological prophylactic anticoagulants and mechanical therapies such as pneumatic compression devices can help prevent venous thromboembolism and other thrombotic events. Thrombotic events due to COVID-19, their prevention and management, are the focus of this paper, with the prospect of providing insights into this relatively unexplored area.

Anticoagulation in COVID – 19: An Update

The Journal of Critical Care Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Anticoagulation in COVID \u2013 19: An Update"}

The novel coronavirus disease, 2019 (COVID – 19) evolved as an unprecedented pandemic. The severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2)...

Anticoagulation in COVID – 19: An Update

Article Category: Review

Pubblicato online: 07 nov 2020

Pagine: 217 - 223

Ricevuto: 14 lug 2020

Accettato: 16 set 2020

DOI: https://doi.org/10.2478/jccm-2020-0033

Parole chiave
COVID-19, anticoagulation, venous thromboembolism, SARS-CoV-2, intensive care unit

© 2020 Nishant R Tiwari, Khalid I Khatib, Subhal B Dixit, Prajay K Rathore, Sameer Melinkeri, Abhijeet Ganapule, Kapil S Borawake, Ujwala Mhatre, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Anticoagulation in COVID – 19: An Update

Article Category: Review

Pubblicato online: 07 nov 2020

Pagine: 217 - 223

Ricevuto: 14 lug 2020

Accettato: 16 set 2020

DOI: https://doi.org/10.2478/jccm-2020-0033

Parole chiaveCOVID-19, anticoagulation, venous thromboembolism, SARS-CoV-2, intensive care unit

© 2020 Nishant R Tiwari, Khalid I Khatib, Subhal B Dixit, Prajay K Rathore, Sameer Melinkeri, Abhijeet Ganapule, Kapil S Borawake, Ujwala Mhatre, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Parole chiave
COVID-19, anticoagulation, venous thromboembolism, SARS-CoV-2, intensive care unit